Prescription drug shortage
- The Hill
People who were eligible for a monkeypox vaccine but did not receive one were about 14 times more likely to become infected than those who were vaccinated, according to preliminary data released Wednesday by the Centers for Disease Control and Prevention (CDC). While extremely limited, the figures offer an initial look at the effectiveness of…
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
Data from Eisai and its partner Biogen are startling because their drug lecanemab slowed cognitive decline, and suggest that a theory that seemed all but disproved still has legs.
- Reuters Videos
STORY: “The report of this successful phase three trial in early Alzheimer's disease will change the landscape of Alzheimer's treatment in this country and worldwide".The results of a key Alzheimer’s drug trial on Wednesday – have reignited decades old hopes that targeting a specific protein helps slow down the fatal brain disease. Eisai Co and Biogen said their experimental drug significantly slowed progress of the disease by 27% compared to a placebo. Offering the promise of an effective treatment to desperate patients and their families. Dr. Lawrence Honig, professor of Neurology at Columbia University Medical Center was one of the investigators on this trial: “What's significant about it is that given that the doses that was given in the fashion it was given over the time period it was given and to the people it was given in this diverse population, it did manage to slow down the clinical progression. Functionally and cognitively, it seems they did better. And so that is a dramatic result. And we hope, is the first step towards many drugs that we might use separately or together to try to improve the plight of people affected by this disease.”Nearly all Alzheimer's drugs have stumbled in trials.Doctors are now hopeful that by removing this particular protein in the brain with this new drug, they can delay the progression of Alzheimers – which affects an estimated 55 million people worldwide. “We would be all very pleased to have a drug that reversed Alzheimer's disease and made people back to normal. But that does seem a little bit far off. We would even be very, very happy right now to have a drug that stopped it cold. And that even seems a little bit far off. But at the moment, we seem to have a drug, lecanemab, that seems to decrease the speed of progression. And I think that's an enormous advance in and of itself beyond the symptomatic medications that we've been using to date.”
- NBC News
Alzheimer's drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
- Motley Fool
Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN). Let's consider why these three biotechs are solid buys for the next decade.
- Motley Fool
Investors on Wall Street continued to have doubts about when the stock market is likely to recover, as ongoing worries about inflation, interest rates, and the global financial system have everyone on edge. Biotech stocks have been among those hit hardest by the bear market in 2022, but Biogen (NASDAQ: BIIB) announced good news in a key clinical trial that has huge implications for those suffering from a harsh and debilitating disease. Biogen's favorable outcome also gave industry peer Eli Lilly (NYSE: LLY) a boost, on optimism that a new way of coming up with important treatments could spur further successes.
- Motley Fool
If so, it was probably for something like Berkshire Hathaway (NYSE: BRK.A), with an eye-popping price of $419,020 per share. Thankfully, there are much cheaper companies to buy, and some of them might even grow a bit faster than Warren Buffett's business. With its shares trading for around $13, having gained 139% in the past 12 months, Catalyst Pharmaceuticals (NASDAQ: CPRX) is a little-known biotech stock that's positioned to keep paying off for investors thanks to its progress in treating a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS).
Pharmaceutical companies Eisai and Biogen said they plan to publish the findings in a peer-reviewed medical journal.
- Reuters Videos
STORY: Shares of Biogen soared more than 40% on Wednesday - after a surprise successful trial of its experimental Alzheimer's drug.Trial results released late Tuesday for lecanemab, which Biogen developed with Japan's Eisai, showed the experimental drug slowed the advancement of Alzheimer's by 27% compared with a placebo, in a large trial of patients in the early stages of the disease.The drug targets a toxic protein plaque that has long been considered crucial to arresting the progression of the fatal brain disease, but previous attempts have led to failure after failure. But analysts hailed Tuesday's trial results as an unequivocal win and could mark a rare victory in the search for a treatment for Alzheimer's after years of clinical failures. Dr. Stephen Salloway is professor of neurology and psychiatry at the Warren Alpert Medical School at Brown University."Well, it's a big moment in the fight against Alzheimer's disease. This is the first pivotal trial of an Alzheimer's drug to come to completion to show substantial amyloid lowering, which is the target, and to demonstrate clear clinical benefits. So it's a ray of hope for people facing early stages of Alzheimer's."Shares of Biogen were on track to add more than $10 billion to its market cap and erase all of its losses this year. Shares of Eisai also jumped following the news, climbing 17% to the daily limit in Tokyo. Shares of rival companies Eli Lilly and Roche also gained, as the latest results raised hope for success in trials testing their Alzheimer's drugs.Shares of smaller Alzheimer's drug developers jumped as well, with Prothena and Acumen Pharmaceuticals each climbing by more than 60%.
- Motley Fool
These businesses might be slightly "boring," but that may just be a good thing in today's market.
The migraine drugmaker in May agreed to an $11.6 billion acquisition deal by Pfizer Inc, which plans to spin off its non-migraine drugs into a new publicly traded company. On Thursday, Biohaven said its drug for ALS did not achieve statistically significant improvement in patients' performance of daily activities compared to a placebo in a mid-to-late-stage trial. ALS is a progressive and life-threatening neuromuscular disease, and the average age for survival is 3-5 years after the onset of first symptoms.
- The Daily Beast
Joe Raedle/GettyPatients who have been vaccinated against the monkeypox virus were 14 times less likely to become infected than those who had not been vaccinated, according to initial data released by the Centers for Disease Control and Prevention on Wednesday, which public health officials say should provide “a level of cautious optimism” that the vaccine may help slow the spread of the virusDr. Rochelle Wolensky, director of the Centers for Disease Control and Prevention, told reporters on Wed
- Business Insider
Lecanemab, a drug made by Eisai and Biogen, was observed in a large-scale trial to have slowed the disease's progression by 27% over 18 months.
- Associated Press
At-risk people who received a single dose of the monkeypox vaccine in U.S. efforts against the virus appeared to be significantly less likely to get sick, public health officials announced Wednesday, even as they urged a second dose for full protection. It was the first look public health officials have offered into how the Jynneos vaccine is affecting monkeypox, a virus that is primarily spread among men who have sex with infected men. “These new data provide us with a level of cautious optimism that the vaccine is working as intended,” Rochelle Walensky, director of the Centers for Disease Control and Prevention, said Wednesday.
The late-stage trial found the experimental drug, lecanemab, slowed the rate of cognitive decline in patients by 27%.
The COVID-19 vaccine increases menstrual cycle by a day or nearly 4 days if you receive both shots in 1 cycle. The changes are temporary. Study raises awareness
(Reuters) -Biogen Inc was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's drug it developed with Eisai was hailed as an unequivocal win by analysts. The trial results released on late Tuesday could mark a rare victory in the search for a treatment for the memory-robbing disease after years of clinical failures. Biogen's stock surged 35.4% to $267.61 in early U.S. trading, putting it on track to erase all of its losses this year.
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai and Biogen BIIB said Wednesday that their drug, lecanemab, reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer's.
The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly. Eisai Co Ltd and Biogen Inc said their experimental drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, a rare positive outcome in a field littered with failure. The read-out is supportive of a longstanding but controversial theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with Alzheimer's can delay the progression of the most common form of dementia, which affects an estimated 55 million people globally.